You are here: Industry Insights > Idorsia

News List

Idorsia submits investigational insomnia treatment daridorexant to the EMA pharmatimes
March 03, 2021
Swiss biotech company Idorsia has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its investigational insomnia treatment daridorexant.
Santhera to Obtain Worldwide Rights to Vamorolone americanpharmaceuticalreview
September 07, 2020
Santhera Pharmaceuticals has signed agreements with Idorsia and ReveraGen BioPharma, making Santhera a direct license holder of vamorolone.
Santhera obtains exclusive licence to DMD drug vamorolone pharmaceutical-technology
September 04, 2020
Santhera Pharmaceuticals has entered agreements with Idorsia and ReveraGen BioPharma to gain exclusive global rights to Duchenne muscular dystrophy (DMD) drug, called vamorolone.
Idorsia Partners with Syneos Health contractpharma
September 01, 2020
Idorsia Ltd and Syneos Health have formed a commercial relationship for the U.S. commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia.
Idorsia Establishes US Commercial Operations, Leadership Team americanpharmaceuticalreview
July 27, 2020
Idorsia announced its expansion in the United States by establishing commercial operations. Located in Radnor, PA, the company has been established to further develop and embed Idorsia’s budding global commercial organization.
Idorsia's selatogrel hits goals in phase 2 cardiovascular trials fiercebiotech
December 25, 2018
Idorsia's P2Y12 receptor antagonist selatogrel has significantly inhibited platelet aggregation in two phase 2 trials. The primary endpoint successes in patients with ....
J&J snaps up Idorsia’s resistant hypertension candidate, paying $230M fiercebiotech
December 05, 2017
Swiss biotech Idorsia spun out of Actelion before it was taken over by Johnson & Johnson earlier this year, but the big pharma has confirmed it will still play a big part in one of its lead products.